Author name: kcahill@epl-inc.com

Reading Time: 4 minutesExperimental Pathology Laboratories, Inc. (EPL), Aclairo Pharmaceutical Development Group, Inc. (Alcairo), and Dr. Ada H.C. Kung with Expedient Solutions International (ESI) announce a new strategic alliance to enhance Preclinical Pathology and Regulatory Consulting Services to the Greater China pharmaceutical and biotechnology industry.  This alliance is targeted to expand and enhance EPL, Aclairo, and ESI’s capabilities […]

Reading Time: 2 minutesExperimental Pathology Laboratories, Inc. (EPL®) is proud to announce that Dr. Paul Snyder has been elected as President of the Society of Toxicologic Pathology (STP).  He will begin serving on the Executive Committee starting in June 2017 along with Mark J. Hoenerhoff (NIEHS) and Stacey Fossey (AbbVie) who will serve four-year terms as Councilors.  Dr.

Reading Time: < 1 minuteEPL will once again be exhibiting at ToxExpo™ in Baltimore from March 13-15, 2017.  If you are attending the 56th Annual Society of Toxicology Meeting, please visit our teams from EPL and Aclairo; we will be exhibiting in Booth #2332. Please stop by and visit EPL if you are in Baltimore!  For more information about the SOT,

Reading Time: < 1 minuteEPL is pleased to announce that Dr. Tom Steinbach will serve as Vice President of EPL, Inc.  As EPL Vice President, Dr. Steinbach will work with EPL’s President and other corporate officers to formulate and implement EPL’s strategic goals.  He will continue to oversee all operations in EPL’s North Carolina facility and manage EPL’s largest

Reading Time: 2 minutesThe eye and the ocular adnexa are common target organs in toxicology studies, but the appropriate evaluation of ocular tissues is a specialized endeavor.   Compared to routine toxicity studies, ocular toxicity studies require methodological modifications at almost every stage from study design to the final pathology report. EPL has extensive experience in the processing and

Reading Time: 2 minutesStereology is a tool for obtaining unbiased estimates of object numbers and/or sizes within three-dimensional regions of interest.  For biological samples, quantitative measurements are potentially more objective and accurate when compared to traditional semi-quantitative grading of findings by pathologists (i.e., scoring of morphologic changes as minimal, mild, moderate, or severe).  Although both approaches require high

Reading Time: 2 minutesCompanies who outsource the histopathology component of their valuable studies need to know that the work will be performed to the highest quality standards, on time, and at competitive prices.  Although claims of quality are easily made, true quality can be a difficult metric to gauge.  So let’s look at the evidence. Unlike its few

Reading Time: < 1 minuteEPL is pleased to announce the promotion of Dr. Kathleen Funk to President of EPL on June 1, 2016.  Dr. Funk has served as the Chief Operating Officer since 2014.  Dr. Funk is a graduate of the Virginia-Maryland Regional College of Veterinary Medicine and also holds a PhD in Comparative Pathology from the University of

Reading Time: 2 minutesEPL announces a newly formed strategic alliance with Histion, an Everett, Washington based preclinical laboratory specializing in GLP-compliant routine and specialty histology and evaluation services.  This alliance is specifically targeted to expand and enhance EPL’s and Histion’s capabilities to an ever expanding area of medical device and novel biomaterial testing.  Although Histion specializes in processing

Reading Time: 3 minutesExperimental Pathology Laboratories, Inc. (EPL®) established EPL Northeast on February 8, 2016. This office is headed by Dr. Heath Thomas who was formerly Vice President of Safety Assessment at GlaxoSmithKline. The Northeast office is located outside of Philadelphia at 125 Chinaberry Lane, Collegeville, PA. With this location, Dr. Thomas will be able to provide local